MedTrace Logo

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

NCT05620043 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-15

Study results available
· View outcomes & findings →

Summary

To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy

Conditions

  • Gene Expression

Interventions

DEVICE

Sculptra

Biostimulator

DEVICE

Radiesse Plus

Semi-permanent filler

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Jill S Waibel, MD · Miami Dermatology & Laser Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2023-07-25
Completion
2023-11-06
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620043 on ClinicalTrials.gov